Amphastar Pharmaceuticals (AMPH) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
1 Jun, 2026Opening remarks and agenda
Meeting opened by CFO William Peters, with Dr. Mary Luo acting as chairperson.
Introduction of board members, executive officers, and key management in attendance.
Outside counsel, independent auditor, and inspector of election introduced.
Agenda included election of directors, ratification of auditor, advisory votes on executive compensation, and frequency of future advisory votes.
Board and executive committee updates
Three Class I directors nominated for re-election to serve until 2029.
Board recommended voting in favor of all proposals on the agenda.
Shareholder proposals
Proposals included election of directors, ratification of auditor, advisory vote on executive compensation, and advisory vote on frequency of future compensation votes.
Latest events from Amphastar Pharmaceuticals
- Transitioning to proprietary drugs, expanding R&D, and targeting major product launches next year.AMPH
16th Annual East Coast IDEAS Conference10 Jun 2026 - Exclusive launches and pipeline innovation drive growth despite pricing headwinds.AMPH
Jefferies Global Healthcare Conference 20263 Jun 2026 - Branded growth, pipeline launches, and R&D drive long-term value and innovation.AMPH
Barclays 28th Annual Global Healthcare Conference14 May 2026 - Proprietary and biosimilar pipeline expansion and mitigation of BAQSIMI issues drive growth.AMPH
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenue was flat at $171.2M, with lower margins and strong pipeline activity.AMPH
Q1 20268 May 2026 - Baqsimi and Primatene Mist drive growth, with new launches and global expansion fueling profitability.AMPH
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay proposals.AMPH
Proxy filing13 Apr 2026 - Shareholders will vote on directors, auditor ratification, and executive pay, with board support for all.AMPH
Proxy filing13 Apr 2026 - BAQSIMI® growth and new launches drive 2026 outlook despite margin and legacy product headwinds.AMPH
Q4 20258 Apr 2026